FDA 'Consistency' Is Industry Watchword For Promoting Effective Drug Development
Executive Summary
Pharma companies and associations cite numerous examples of getting inconsistent advice across review divisions, including the number of clinical trials required for rare disease drugs and acceptance of innovative clinical trial designs and novel endpoints.